Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
NCT07828860
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
Safety and Efficacy of Soquelitinib in Adults with Hidradenitis Suppurativa
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hidradenitis Suppurativa (HS)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Corvus Pharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Kentucky · 2
- Clinical Site 1 · Bowling Green, KY
- Clinical Site 2 · Owensboro, KY
New York · 2
- Clinical Site 5 · New York, NY
- Clinical Site 4 · The Bronx, NY
North Dakota · 1
- Clinical Site 11 · Fargo, ND
Ohio · 1
- Clinical Site 10 · Mayfield Heights, OH
Pennsylvania · 2
- Clinical Site 6 · Camp Hill, PA
- Clinical Site 8 · Philadelphia, PA
Tennessee · 1
- Clinical Site 7 · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.